Cephalexin Failure Rate Similar for Morbidly Obese, Non-Obese

This article originally appeared here.
Share this content:
Cephalexin Failure Rate Similar for Morbidly Obese, Non-Obese
Cephalexin Failure Rate Similar for Morbidly Obese, Non-Obese

TUESDAY, May 31, 2016 (HealthDay News) -- For patients receiving cephalexin monotherapy for non-purulent cellulitis, the rate of therapeutic failure does not differ for morbidly obese and non-obese, according to a study published online May 19 in the Journal of Clinical Pharmacy and Therapeutics.

Kimberly R. Kaufman, Pharm.D., from the Minneapolis VA Health Care System, and colleagues conducted a single-center, retrospective cohort analysis involving adult patients hospitalized or under inpatient observation who received cephalexin monotherapy for non-purulent cellulitis. Patients were stratified according to body mass index (BMI), where BMI <30 kg/m² was defined as non-obese and BMI ≥40 kg/m² was defined as morbidly obese. Ninety-four patients were included, of whom 69 were non-obese and 25 were morbidly obese.

The researchers found that the rate of therapeutic failure was 20 percent in the morbidly obese group and 14.5 percent in the non-obese group (P = 0.53). In response to therapeutic failure with cephalexin, patients most commonly had extended or additional antibiotics prescribed.

"Cephalexin failure rates for cellulitis did not differ statistically between morbidly obese and non-obese patients," the authors write. "Until further study with a larger sample size is completed, empiric adjustment of cephalexin dosing based solely on BMI may not be necessary."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

FDA Approves 'Artificial Pancreas' for Type 1 Diabetes

FDA Approves 'Artificial Pancreas' for Type 1 Diabetes

MiniMed 670G hybrid closed loop system automatically monitors glucose, delivers insulin

More Evidence HPV Vaccine Protects Against Cervical Cancer

More Evidence HPV Vaccine Protects Against Cervical Cancer

Protection appears to occur even when only one or two of the recommended doses are given

Prescribed NSAIDs Tied to Higher Heart Failure Risk

Prescribed NSAIDs Tied to Higher Heart Failure Risk

Study of millions of health records suggests an association

is free, fast, and customized just for you!

Already a member?

Sign In Now »